Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Oct;68(4):1106–1107. doi: 10.1172/JCI110335

Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.

T Wasada, K McCorkle, V Harris, K Kawai, B Howard, R H Unger
PMCID: PMC370900  PMID: 7287903

Abstract

To determine whether gastric inhibitory polypeptide (GIP) promotes the clearance of chylomicron triglycerides (TG) from the circulation in dogs, chyle collected from donor dogs via a thoracic duct fistula was infused at a rate of 2 ml/min i.v. into normal recipient dogs during an infusion of either porcine GIP (1 microgram/kg per h) or saline as a control. In the GIP-infused dogs the rise in plasma TG was significantly below that of the control animals [mean peak of 36 +/- 4 mg/dl vs. 82 +/- 18 mg/dl (P less than 0.05)]. It is concluded that GIP exerts an effect upon the removal of chylomicron TG from the blood. The results suggest that GIP may play a physiologic role in the disposition of ingested fat.

Full text

PDF
1106

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973 May;19(5):476–482. [PubMed] [Google Scholar]
  2. Böttger I., Dobbs R., Faloona G. R., Unger R. H. The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity. J Clin Invest. 1973 Oct;52(10):2532–2541. doi: 10.1172/JCI107444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dupre J., Ross S. A., Watson D., Brown J. C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973 Nov;37(5):826–828. doi: 10.1210/jcem-37-5-826. [DOI] [PubMed] [Google Scholar]
  4. Eckel R. H., Fujimoto W. Y., Brunzell J. D. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes. 1979 Dec;28(12):1141–1142. doi: 10.2337/diab.28.12.1141. [DOI] [PubMed] [Google Scholar]
  5. Falko J. M., Crockett S. E., Cataland S., Mazzaferri E. L. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab. 1975 Aug;41(2):260–265. doi: 10.1210/jcem-41-2-260. [DOI] [PubMed] [Google Scholar]
  6. Harris V., Conlon J. M., Srikant C. B., McCorkle K., Schusdziarra V., Ipp E., Unger R. H. Measurements of somatostatin-like immunoreactivity in plasma. Clin Chim Acta. 1978 Jul 15;87(2):275–283. doi: 10.1016/0009-8981(78)90348-0. [DOI] [PubMed] [Google Scholar]
  7. Pederson R. A., Schubert H. E., Brown J. C. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes. 1975 Dec;24(12):1050–1056. doi: 10.2337/diab.24.12.1050. [DOI] [PubMed] [Google Scholar]
  8. Rouiller D., Schusdziarra V., Harris V., Unger R. H. Release of pancreatic and gastric somatostatin-like immunoreactivity in response to the octapeptide of cholecystokinin, secretin gastric inhibitory polypeptide, and gastrin-17 in dogs. Endocrinology. 1980 Aug;107(2):524–529. doi: 10.1210/endo-107-2-524. [DOI] [PubMed] [Google Scholar]
  9. YALOW R. S., BERSON S. A. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960 Jul;39:1157–1175. doi: 10.1172/JCI104130. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES